Melinta Therapeutics Inc. buy tamam
Start price
27.03.17
/
50%
€92.46
Target price
27.09.17
€225.50
Performance (%)
-25.61%
End price
27.09.17
€68.78
Summary
This prediction ended on 27.09.17 with a price of €68.78. The prediction for Melinta Therapeutics Inc. disappointed with a performance of -25.61%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Melinta Therapeutics Inc. | - | - | - | - |
| iShares Core DAX® | 2.901% | 3.653% | 5.756% | 49.364% |
| iShares Nasdaq 100 | 4.597% | 3.057% | 36.946% | 89.089% |
| iShares Nikkei 225® | 10.422% | 12.613% | 64.975% | 72.729% |
| iShares S&P 500 | 2.574% | 1.362% | 25.173% | 65.392% |
Comments by tamam for this prediction
In the thread Melinta Therapeutics Inc. diskutieren
Cempra, either Merck or Pfizer is interested in buying it
Bullish macht mich auch der Chartverlauf:
The daily price of CEMP shows a steadily rising trend off the late December lows on strong share accumulation. 4.75 is near-term resistance -- the high set by the Phase III endpoint news by Fusidic Acid -- and shares are now holding steady at 4.10.
(Laufzeit überschritten)
Stopped prediction by tamam for Melinta Therapeutics Inc.
Melinta Therapeutics Inc.
Start price
Target price
Perf. (%)
€426.53
21.01.16
21.01.16
€676.50
21.07.16
21.07.16
-5.05%
21.07.16
21.07.16
